Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 1
1965 3
1967 2
1969 3
1970 1
1971 1
1972 2
1973 4
1974 5
1975 9
1976 12
1977 2
1978 2
1979 9
1980 9
1981 9
1982 4
1983 8
1984 5
1985 4
1986 7
1987 6
1988 9
1989 15
1990 14
1991 24
1992 25
1993 15
1994 9
1995 13
1996 12
1997 12
1998 27
1999 19
2000 23
2001 16
2002 21
2003 22
2004 28
2005 26
2006 25
2007 28
2008 24
2009 27
2010 41
2011 34
2012 28
2013 27
2014 30
2015 26
2016 27
2017 22
2018 21
2019 20
2020 30
2021 34
2022 28
2023 31
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

884 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Shimoyama T, Lee KW, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Shitara K. Yamaguchi K, et al. Among authors: kojima a. J Clin Oncol. 2023 Feb 1;41(4):816-825. doi: 10.1200/JCO.22.00575. Epub 2022 Nov 15. J Clin Oncol. 2023. PMID: 36379002 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Sakamoto Y, Nishina T, Inaki K, Kuwahara Y, Wada N, Suto F, Arita T, Sugihara M, Tsuchihashi Z, Saito K, Kojima A, Yamaguchi K. Shitara K, et al. Among authors: kojima a. Nat Med. 2024 Jul;30(7):1933-1942. doi: 10.1038/s41591-024-02992-x. Epub 2024 May 14. Nat Med. 2024. PMID: 38745009 Free PMC article. Clinical Trial.
Symmetric peripheral gangrene.
Akamatsu S, Kojima A, Tanaka A, Hayashi K, Hashimoto T. Akamatsu S, et al. Among authors: kojima a. Anesthesiology. 2013 Jun;118(6):1455. doi: 10.1097/ALN.0b013e31826e05a7. Anesthesiology. 2013. PMID: 23059450 Free article. No abstract available.
Predictor of rehabilitation outcome for dysphagia.
Kojima A, Imoto Y, Osawa Y, Fujieda S. Kojima A, et al. Auris Nasus Larynx. 2014 Jun;41(3):294-8. doi: 10.1016/j.anl.2013.12.009. Epub 2014 Feb 20. Auris Nasus Larynx. 2014. PMID: 24560094
884 results